Acción 7325 IRRC CORPORATION
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas IRRC Corporation

Acciones

7325

JP3105230001

Mercado cerrado - Japan Exchange
Otros sitios de cotización
 08:00:00 01/05/2024 		Varia. Cinco días. Varia. 1 de enero.
724 JPY -0,28 % Gráfico intradía de IRRC Corporation -0,96 % +12,07 %
2023 IRRC Corporation (TSE:7325) completó la adquisición de una participación del 80,9% en Life Assist Co., Ltd. a Orix Life Insurance Corporation. CI
2023 IRRC Corporation (TSE:7325) anuncia una recompra de acciones por 200.000 acciones, que representan el 2,38% por ¥160 millones. CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
IRRC Corporation's Equity Buyback announced on August 18, 2023, has closed with 200,000 shares, representing 2.39% for ¥140.90 million.
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
Henlius Biotech, Inc. - Results from Four Phase 1/2 Clinical Trials of Henlius Innovative Products Released at 2023 ESMO Asia
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.
IRRC Corporation completed the acquisition of 80.9% stake in Life Assist Co., Ltd. from Orix Life Insurance Corporation.
IRRC Corporation announces an Equity Buyback for 200,000 shares, for ¥160 million.
IRRC Corporation authorizes a Buyback Plan.
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
IRRC Corporation's Equity Buyback announced on February 14, 2023, has closed with 300,300 shares, representing 3.48% for ¥228.63 million.
IRRC Corporation signed a basic agreement to acquire a 80.9% stake in Life Assist Co., Ltd. from Orix Life Insurance Corporation for approximately ¥400 million.
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
IRRC Corporation Reports Earnings Results for the Nine Months Ended March 31, 2023
Tranche Update on IRRC Corporation's Equity Buyback Plan announced on February 14, 2023.
CStone Announces Publication of GEMSTONE-201 Study Results for Sugemalimab Monotherapy in the Treatment of Relapsed, Refractory Extranodal NK/T-Cell Lymphoma in Journal of Clinical Oncology
IRRC Corporation announces an Equity Buyback for 500,000 shares, representing 5.74% for ¥400 million.
IRRC Corporation authorizes a Buyback Plan.
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in Japan
CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022
IRRC : Pennsylvania Takes Next Step Toward Cap-and-Trade Amid Resistance
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 7325
  4. Noticias IRRC Corporation
  5. Otros idiomas